Works by Miyamoto, Hirotaka


Results: 21
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Authors' Reply to Noguchi et al. Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors Used in Patients with Diabetes and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database": Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: T. Sakamoto et al

    Published in:
    Clinical Drug Investigation, 2025, v. 45, n. 1, p. 47, doi. 10.1007/s40261-024-01414-7
    By:
    • Sakamoto, Toshiaki;
    • Miyamoto, Hirotaka;
    • Hashizume, Junya;
    • Akamatsu, Hayato;
    • Akagi, Tomoaki;
    • Kodama, Yukinobu;
    • Hamano, Hirofumi;
    • Zamami, Yoshito;
    • Ohyama, Kaname
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression.

    Published in:
    Journal of Gastroenterology, 2023, v. 58, n. 1, p. 53, doi. 10.1007/s00535-022-01929-w
    By:
    • Sakai, Norihiro;
    • Kamimura, Kenya;
    • Miyamoto, Hirotaka;
    • Ko, Masayoshi;
    • Nagoya, Takuro;
    • Setsu, Toru;
    • Sakamaki, Akira;
    • Yokoo, Takeshi;
    • Kamimura, Hiroteru;
    • Soki, Hiroyuki;
    • Tokunaga, Ayako;
    • Inamine, Tatsuo;
    • Nakashima, Mikiro;
    • Enomoto, Hatsune;
    • Kousaka, Kazuki;
    • Tachiki, Hidehisa;
    • Ohyama, Kaname;
    • Terai, Shuji
    Publication type:
    Article
    21